Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Chan, Catherine P. K., Chang, Andrea, Zhou, Zheng-Yi, Xie, Jipan, Gibbs, MeaghanVolume:
18
Journal:
Cost Effectiveness and Resource Allocation
DOI:
10.1186/s12962-020-00244-6
Date:
December, 2020
File:
PDF, 1.56 MB
2020